-
CTXR Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Citius Pharmaceuticals (CTXR)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 24 | Sep 23 | Sep 22 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.10 mm | 1.10 mm | 1.10 mm | 1.10 mm | 1.10 mm | 1.10 mm |
Cash burn (monthly) | 717.27 k | 1.60 mm | 3.35 mm | 3.56 mm | 1.58 mm | 2.23 mm |
Cash used (since last report) | 1.48 mm | 3.31 mm | 6.91 mm | 7.34 mm | 3.25 mm | 4.61 mm |
Cash remaining | -380.19 k | -2.21 mm | -5.81 mm | -6.24 mm | -2.15 mm | -3.51 mm |
Runway (months of cash) | -0.5 | -1.4 | -1.7 | -1.8 | -1.4 | -1.6 |
13F holders | Current |
---|---|
Total holders | 59 |
Opened positions | 9 |
Closed positions | 21 |
Increased positions | 7 |
Reduced positions | 25 |
13F shares | Current |
---|---|
Total value | 11.74 bn |
Total shares | 23.60 mm |
Total puts | 32.10 k |
Total calls | 83.10 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 7.28 mm | $3.64 bn |
Vanguard | 6.44 mm | $3.23 bn |
Geode Capital Management | 1.88 mm | $940.79 mm |
BlackRock | 1.81 mm | $903.95 mm |
Millennium Management | 1.16 mm | $579.95 mm |
Advisor | 931.83 k | $466.45 mm |
Squarepoint Ops | 659.38 k | $330.09 mm |
STT State Street | 581.80 k | $291.25 mm |
NTRS Northern Trust | 319.36 k | $159.87 mm |
Chelsea Counsel | 281.30 k | $140.82 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Nov 24 | Holuka Eugene Myron | Stock Option (Right to Purchase Common Stock) Common Stock | Grant | Acquire A | No | No | 0.38 | 125,000 | 47.50 k | 125,000 |
7 Nov 24 | Webb Carol | Stock Option (Right to Purchase Common Stock) Common Stock | Grant | Acquire A | No | No | 0.38 | 125,000 | 47.50 k | 125,000 |
7 Nov 24 | Robert Joseph Smith | Stock Option (Right to Purchase Common Stock) Common Stock | Grant | Acquire A | No | No | 0.38 | 125,000 | 47.50 k | 125,000 |
7 Nov 24 | Mcgrath Dennis M | Stock Option (Right to Purchase Common Stock) Common Stock | Grant | Acquire A | No | No | 0.38 | 125,000 | 47.50 k | 125,000 |
7 Nov 24 | Myron Czuczman | Stock Option (Right to Purchase Common Stock) Common Stock | Grant | Acquire A | No | No | 0.38 | 300,000 | 114.00 k | 300,000 |